finance

Barclays downgrades Reata Pharma to 'equalweight' with a price target of $172.00




Barclays downgrades Reata Pharma to 'equalweight' with a price target of $172.00



READ SOURCE

Readers Also Like:  Strathclyde spin-out seeks £10 million funding for growth

This website uses cookies. By continuing to use this site, you accept our use of cookies.